Agios initiates trial of mitapivat in pediatric PKD patients with no transfusion history
Agios Pharmaceuticals is conducting a trial to assess mitapivat's efficacy and safety in pediatric patients with PKD who are not regularly transfused.
Asset / Drug
Drug and asset intelligence for Agios with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.